These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
402 related articles for article (PubMed ID: 19885551)
61. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Czuczman MS; Gregory SA Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564 [TBL] [Abstract][Full Text] [Related]
62. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Shi W; Han X; Yao J; Yang J; Shi Y Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365 [TBL] [Abstract][Full Text] [Related]
63. Understanding rituximab function and resistance: implications for tailored therapy. Amoroso A; Hafsi S; Militello L; Russo AE; Soua Z; Mazzarino MC; Stivala F; Libra M Front Biosci (Landmark Ed); 2011 Jan; 16(2):770-82. PubMed ID: 21196202 [TBL] [Abstract][Full Text] [Related]
64. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice. Smith MR; Joshi I; Jin F; Obasaju C BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167 [TBL] [Abstract][Full Text] [Related]
65. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement. Okroj M; Eriksson I; Österborg A; Blom AM Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205 [TBL] [Abstract][Full Text] [Related]
66. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Inagaki A; Ishida T; Yano H; Ishii T; Kusumoto S; Ito A; Ri M; Mori F; Ding J; Komatsu H; Iida S; Ueda R Int J Cancer; 2009 Jul; 125(1):212-21. PubMed ID: 19358282 [TBL] [Abstract][Full Text] [Related]
67. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL. Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982 [TBL] [Abstract][Full Text] [Related]
68. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686 [TBL] [Abstract][Full Text] [Related]
69. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647 [TBL] [Abstract][Full Text] [Related]
70. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Carnahan J; Stein R; Qu Z; Hess K; Cesano A; Hansen HJ; Goldenberg DM Mol Immunol; 2007 Feb; 44(6):1331-41. PubMed ID: 16814387 [TBL] [Abstract][Full Text] [Related]
71. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726 [TBL] [Abstract][Full Text] [Related]
72. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Shan D; Gopal AK; Press OW Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831 [TBL] [Abstract][Full Text] [Related]
73. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. Pievani A; Belussi C; Klein C; Rambaldi A; Golay J; Introna M Blood; 2011 Jan; 117(2):510-8. PubMed ID: 21048157 [TBL] [Abstract][Full Text] [Related]
74. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Shan D; Ledbetter JA; Press OW Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475 [TBL] [Abstract][Full Text] [Related]
75. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019 [TBL] [Abstract][Full Text] [Related]
76. Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. Odabaei G; Chatterjee D; Jazirehi AR; Goodglick L; Yeung K; Bonavida B Adv Cancer Res; 2004; 91():169-200. PubMed ID: 15327891 [TBL] [Abstract][Full Text] [Related]
77. Involvement of NF-κB in mediating the anti-tumour effects of combretastatins in T cells. Pollock JK; Greene LM; Nathwani SM; Kinsella P; O'Boyle NM; Meegan MJ; Zisterer DM Invest New Drugs; 2018 Aug; 36(4):523-535. PubMed ID: 29460212 [TBL] [Abstract][Full Text] [Related]
78. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Alas S; Bonavida B Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352 [TBL] [Abstract][Full Text] [Related]
79. Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Zhang N; Khawli LA; Hu P; Epstein AL Clin Cancer Res; 2005 Aug; 11(16):5971-80. PubMed ID: 16115941 [TBL] [Abstract][Full Text] [Related]
80. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Dalle S; Reslan L; Besseyre de Horts T; Herveau S; Herting F; Plesa A; Friess T; Umana P; Klein C; Dumontet C Mol Cancer Ther; 2011 Jan; 10(1):178-85. PubMed ID: 21220500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]